Videos

Rohan Garje, MD, explains some of the differences between the sarcomatoid and classic carcinoma of the bladder.

Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.

The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.

Eric A. Singer, MD, MS, discusses which patients he believes would benefit most from adjuvant therapy for high-risk renal cell carcinoma.

Concluding the discussion, Dr Rana McKay discusses the current state of advanced RCC, potential breakthroughs, and best practices for optimal patient outcomes.

Rana McKay, MD, provides insights into decision-making strategies and consideration for treatment sequencing in advanced RCC.

Discussion on triplet therapy regimens in advanced RCC and how progressing therapeutic studies can impact its future use.

Yi Lin MD, PhD explains how results from CARTITUDE-1 impact the treatment landscape for relapsed or refractory multiple myeloma.

Expert perspective on CheckMate 9ER quality of life data and treatment implications for patients with advanced RCC.

Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.

Reflection on biomarkers, treatment resistance, and other unmet needs in 1L treatment of advanced RCC by Rana R. McKay, MD.

Dr Rana McKay provides insight on preferred therapeutic options for first-line treatment of RCC and how patient risk stratification influences decision making.

Rana R. McKay, MD, reflects on the landscape of advanced RCC, discusses histology, subsets of kidney cancer, and IMDC criteria for prognostic stratification.

Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.

Before closing out their module on ESR1 mutation, panelists identify its impact on treatment options for patients diagnosed with HR+/HER2- metastatic breast cancer.

In the context of ESR1 mutation in HR+/HER2- metastatic breast cancer, key opinion leaders consider ideal testing modalities and timing to improve patient outcomes.

John Diaz, discusses key targets for cervical cancer and ovarian cancer.

Federico Albrecht, MD, comments on clinical trials supporting the use of PD-L1 inhibitor therapy in combination with standard chemotherapy for the treatment of patients with extensive-stage small cell lung cancer.

Andreas Varkaris, MD, PhD, discusses PIK3CA mutations in breast cancer and the novel therapies being developed to treat these tumors.

Andrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.

Samer A. Srour, MD, MS, discusses what challenges need to be faced when moving forward with the phase 1 trial of Orca-Q in patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.

Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.

Key takeaways from recent data updates from the PRIMA and PAOLA-1 trials investigating PARP inhibitors in ovarian cancer.

Chad A. Hamilton, MD, shares strategies for managing gastrointestinal toxicities and fatigue for patients receiving PARP inhibitors for the treatment of ovarian cancer.

Clinical insights on adverse effects seen with PARP inhibitors in the treatment of patients with ovarian cancer.

An overview of factors that influence the initiation of maintenance therapy for patients with ovarian cancer.

Chad A. Hamilton, MD, discusses how clinical trial data inform treatment selection for patients with ovarian cancer.

A comprehensive overview of the maintenance therapy landscape in ovarian cancer, with a focus on clinical trials investigating bevacizumab, olaparib, and niraparib.

An expert gynecologic oncologist reviews guideline recommendations for molecular testing in ovarian cancer and shares his testing practices.

Chad A. Hamilton, MD, presents the case of a 49-year-old woman with BRCA wild-type ovarian cancer and offers his initial impressions.